Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Zh Evol Biokhim Fiziol ; 48(6): 573-8, 2012.
Article in Russian | MEDLINE | ID: mdl-23401968

ABSTRACT

In behavioral experiments on bottle-nosed dolphins there was evaluated efficiency of identification of the low frequency noises that represent a certain rhythmical sequence of impulses, at destabilization of their spectra by method of frequency wobble. Results of the experiments have shown that disturbance of spectra structure at erosion of its discrete components does not lead to a decrease of efficiency of the noise identification, which indicates the greater significance of the time, rather than spectral mechanisms at processing of the complex acoustic signals by the dolphin auditory system.


Subject(s)
Auditory Perception/physiology , Bottle-Nosed Dolphin/physiology , Hearing/physiology , Acoustic Stimulation , Animals , Noise
2.
Aviakosm Ekolog Med ; 46(5): 55-8, 2012.
Article in Russian | MEDLINE | ID: mdl-23405422

ABSTRACT

To optimize the design of SHF-based potable water disinfection and heating subsystem within the life support system (LSS), computer modeling of the super-high frequency electromagnetic field in SHF-based waveguide-coaxial and coaxial running water heaters was performed Software package CST Microwave Studio 2010 was used as the main instrument in the investigation. Results of the investigation can contribute to the development and prototyping of an HSF-based water heater as an integral part of advanced life support system for spacecrews


Subject(s)
Disinfection/statistics & numerical data , Ecological Systems, Closed , Heating/statistics & numerical data , Life Support Systems/instrumentation , Software , Space Flight , Carbon Dioxide/chemistry , Computer Simulation , Disinfection/instrumentation , Disinfection/methods , Drinking Water , Electromagnetic Fields , Heating/instrumentation , Heating/methods , Humans , Microwaves , Models, Theoretical
6.
Zh Nevrol Psikhiatr Im S S Korsakova ; 110(11 Pt 1): 17-20, 2010.
Article in Russian | MEDLINE | ID: mdl-21183917

ABSTRACT

We studied efficacy and tolerability of the combined drug omaron (25 mg of cinnarizine and 400 mg of piracetam in one tablet) in patients with multiple sclerosis. The dosage of the drug was 1 tablet 3 times a day during 12 weeks in 33 patients (mean age 35.3±4.2 years) of the index group. A comparison group consisted of 27 patients matched for demographic and clinical characteristics who did not receive nootropics during the study. None of patients included in the study received disease modifying drugs. The significant (p<0.05) decrease in the severity of chronic fatigue syndrome (by 28.6% compared to baseline), improvement (p<0.05) of cognitive functions (increase of MMSE scores by 9.4%) were found in the index group compared to the comparison one. The statistically significant changes in the severity of disability assessed by EDSS were not observed. Omaron was well-tolerated with no serious adverse-effects.


Subject(s)
Cinnarizine/therapeutic use , Fatigue Syndrome, Chronic/drug therapy , Multiple Sclerosis/drug therapy , Piracetam/therapeutic use , Adult , Cinnarizine/adverse effects , Drug Combinations , Fatigue Syndrome, Chronic/etiology , Female , Humans , Male , Middle Aged , Multiple Sclerosis/complications , Piracetam/adverse effects , Treatment Outcome , Young Adult
8.
Zh Nevrol Psikhiatr Im S S Korsakova ; 110(5 Pt 1): 57-60, 2010.
Article in Russian | MEDLINE | ID: mdl-21322181

ABSTRACT

The study included 54 patients with multiple sclerosis, aged from 23 to 53 years (mean age 37.7 +/- 8.5 years). To reduce muscle tension, 34 patients of the main group received tizanidine with the modified release of active substance (sirdalud MR) in dosage one capsule (6 mg) per day. Twenty-two patients of the comparison group received a standard form of tizanidine--sirdalud in tablets (2 mg) 3 times daily. Patients were examined at baseline, 1, 2 and 4 weeks of the treatment and 2 weeks after the end of the trial. The use of different forms of sirdalud had no effect on disability (the EDSS) scores in patients. Spasticity scores (the Ashworth scale) were decreased during the treatment with different forms of sirdalud but sirdalud MR had more stable effect which remained for 2 weeks after the end of treatment (p < 0.05). Significant differences were observed between tolerability of two forms: side-effects (sleepiness, asthenia) were more frequents in patients treated with the standard form of sirdalud (p < 0.05), the rate of their reduction was significantly higher in the sirdalud MR group (p < 0.05).


Subject(s)
Clonidine/analogs & derivatives , Multiple Sclerosis/drug therapy , Muscle Relaxants, Central/therapeutic use , Adult , Clonidine/adverse effects , Clonidine/therapeutic use , Humans , Male , Middle Aged , Multiple Sclerosis/physiopathology , Muscle Relaxants, Central/adverse effects , Muscle Weakness/chemically induced , Muscle Weakness/physiopathology , Severity of Illness Index , Sleep Wake Disorders/chemically induced , Sleep Wake Disorders/physiopathology , Treatment Outcome , Young Adult
9.
Article in Russian | MEDLINE | ID: mdl-19672225

ABSTRACT

External counterpulsation (ECP) - is a non-invasive method of treatment providing the increase of perfusion pressure in coronary and cerebral arteries during diastole and the decrease of vascular resistance during systole. Efficacy of this method in the early rehabilitation period of ischemic stroke was studied for the first-time in Russian Federation. Twenty-six patients, aged 65,9+/-8,7 years, who survived stroke 58--115 (mean 81,6+/-15,6) days ago, were examined. Patients of group 1 (n=7) received 17 sessions of ECP, patients of group 2 (n=9) -- 35 sessions, patients of group 3 -- standard basic therapy without ECP. The maximal effect estimated as the increase of power in paretic extremities by 24,3%, decrease of spasticity by 69,6% and higher Barthel index scores (by 6,9%) as well as the increase of blood flow through inner carotid arteries by 24% (p<0,05) and spine arteries by 14% (p<0,05) were found in group 2. Side-effects of the treatment were not observed.


Subject(s)
Counterpulsation/methods , Regional Blood Flow/physiology , Stroke Rehabilitation , Vascular Resistance/physiology , Aged , Cerebrovascular Circulation/physiology , Coronary Circulation/physiology , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Stroke/diagnosis , Stroke/physiopathology , Tomography, X-Ray Computed , Treatment Outcome
10.
Article in Russian | MEDLINE | ID: mdl-19491816

ABSTRACT

An open comparative study of efficacy and tolerability of velaxin (venlafaxine with prolonged action), which has been prescribed in a single dosage of 75 mg daily during 8 weeks, included 47 patients with subacute and chronic spondylogenic dorsopathy (SD). Degree of pain chronisation and its intensity (The Visual Analogous Scale - VAS and the Verbal Pain Scale - VPS) and levels of daily activity restriction (the modified Pain Disability Questionnaire - PDQ), anxiety and depression were measured. The comparison group consisted of 32 patients with SD matched for clinical characteristics with the main group, who did not receive antidepressants and antiepileptics in the complex treatment of pain syndrome. Scores of VAS, VPS and PDQ in the main group were 69+/-2.9; 2.8+/-0.1 and 44.2+/-3.2 respectively, at baseline; 38.8+/-3.3 (p<0.01); 1.6+/-0.2 (p<0.01) and 26.2+/-2.5 (p<0.01) after 4 weeks and 15.8+/-2.5 (p<0.05); 0.6+/-0.1 (p<0.05) and 11.2+/-1.6 (p<0.01) to the end of treatment. To the 8th week, scores on VAS, VPS and PDQ were significantly low in the main group compared to the controls (p<0.5) and the intensity of pain was reduced by 50% in 40 (85%) patients. No serious side-effects were observed.


Subject(s)
Analgesics/therapeutic use , Antidepressive Agents, Second-Generation/therapeutic use , Cyclohexanols/therapeutic use , Low Back Pain/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adult , Analgesics/administration & dosage , Antidepressive Agents, Second-Generation/administration & dosage , Chronic Disease , Cyclohexanols/administration & dosage , Female , Humans , Low Back Pain/diagnosis , Low Back Pain/diagnostic imaging , Low Back Pain/etiology , Male , Middle Aged , Pain Measurement , Patient Selection , Radiography , Selective Serotonin Reuptake Inhibitors/administration & dosage , Spinal Diseases/complications , Spinal Osteophytosis , Spondylitis , Surveys and Questionnaires , Time Factors , Treatment Outcome , Venlafaxine Hydrochloride
12.
Neurosci Behav Physiol ; 38(9): 933-6, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18975095

ABSTRACT

Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2-3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant (physiological) stimulation of postsynaptic dopamine receptors. To some extent this is provided by Stalevo, which contains levodopa and two enzyme inhibitors: the DDC inhibitor carbidopa and the COMT inhibitor entacapone. The results obtained in the present study demonstrated the advantages of Stalevo over traditional agents in patients with the "wearing off" and "on-off" phenomena.


Subject(s)
Antiparkinson Agents/therapeutic use , Carbidopa/therapeutic use , Catechols/therapeutic use , Levodopa/therapeutic use , Parkinson Disease/drug therapy , Activities of Daily Living , Aged , Carbidopa/adverse effects , Catechols/adverse effects , Drug Combinations , Dyskinesias/drug therapy , Female , Humans , Levodopa/adverse effects , Male , Middle Aged , Motor Activity/drug effects , Outpatients , Severity of Illness Index , Time Factors , Treatment Outcome
13.
Article in Russian | MEDLINE | ID: mdl-18833171

ABSTRACT

The authors review the use of axamon in the complex rehabilitation of neurological patients with movement disorders in the pathology of lumbar spine. Axamon (ipidacrine) stimulates neuromuscular transmission and excitement conduction via nerves and smooth muscles due to the blockade of potassium channels of the excited membrane and cholinesterase inhibition. Authors studied the efficacy of complex therapy of dorsopathy of lumbar spine in 90 patients using axamon, movalis, pantogamum in different combination and manual methodics. Patient's status has been measured clinically and with several scales. The results obtained allow to conclude that the combination of axamon and pantogamum exerts the best theraupetic effect without any side symptoms.


Subject(s)
Aminoquinolines/therapeutic use , Anti-Dyskinesia Agents/therapeutic use , Low Back Pain , Movement Disorders/epidemiology , Adult , Aminoquinolines/administration & dosage , Anti-Dyskinesia Agents/administration & dosage , Female , Humans , Low Back Pain/drug therapy , Low Back Pain/epidemiology , Low Back Pain/physiopathology , Male , Middle Aged , Movement Disorders/diagnosis , Severity of Illness Index
14.
Article in Russian | MEDLINE | ID: mdl-18577932

ABSTRACT

Baclosan (baclofen), a GABA analogue, has been used in the treatment of 20 patients, aged 20-56 years, with a pain syndrome in dorsopathy of lumbar spine. Baclosan has been administered in the increasing dosages (from 10 mg to 30 mg per day) for 4 weeks in conjunction with traditional therapy (symptomatic pharmacotherapy, physiotherapy, reflexotherapy etc).The control group consisted of 10 patients who received only basic therapy (without baclosan). Patient's status has been measured clinically and with several scales. The results obtained allow to conclude that baclosan exerts a positive effect in the pain syndrome caused by dorsopathy. Its inclusion to the complex therapy reduces both the pain intensity and the degree of muscle-tonic tension as well as improves the motor function and emotional state of patients.


Subject(s)
Baclofen , Muscle Relaxants, Central/pharmacology , Muscle Relaxants, Central/therapeutic use , Muscle, Skeletal/drug effects , Muscle, Skeletal/physiopathology , Myofascial Pain Syndromes , Spinal Diseases/etiology , Adult , Baclofen/analogs & derivatives , Baclofen/pharmacology , Baclofen/therapeutic use , Biomechanical Phenomena , Female , Humans , Male , Middle Aged , Myofascial Pain Syndromes/complications , Myofascial Pain Syndromes/drug therapy , Myofascial Pain Syndromes/physiopathology
16.
Article in Russian | MEDLINE | ID: mdl-18427455

ABSTRACT

Despite significant symptomatic effect of levodopa, in most patients the stable 24 hour's effect changed for alterations of movement symptoms (fluctuations, dyskinesia) after 2-3 years of the therapy. These complications may be reduced due to the constant (physiologic) stimulation of post-synaptic dopamine receptors that, to a certain degree, provides the drug stalevo, which contains levodopa and 2 enzyme inhibitors, dopa decarboxylase (carbidopa) and catechol-O-methyltransferase (entacapone). The results of the study demonstrated beneficial effects of stalevo as compared to traditional therapy in patients with "wearing off" and "on-off" phenomena.


Subject(s)
Carbidopa/administration & dosage , Catechols/administration & dosage , Levodopa/administration & dosage , Outpatients , Parkinson Disease/drug therapy , Activities of Daily Living , Aged , Ambulatory Care Facilities , Dose-Response Relationship, Drug , Drug Combinations , Female , Follow-Up Studies , Humans , Male , Parkinson Disease/physiopathology , Severity of Illness Index , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...